Current Infectious Disease Reports最新文献_第3页

An Update on Suppurative Tenosynovitis 化脓性腱鞘炎的最新进展

IF 3.1 4区医学

Current Infectious Disease Reports Pub Date : 2024-01-03 DOI: 10.1007/s11908-023-00826-4

Wissam El Atrouni, Mitchell C. Birt, Rachel Weihe

{"title":"An Update on Suppurative Tenosynovitis","authors":"Wissam El Atrouni, Mitchell C. Birt, Rachel Weihe","doi":"10.1007/s11908-023-00826-4","DOIUrl":"https://doi.org/10.1007/s11908-023-00826-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Suppurative tenosynovitis is a serious infection mostly affecting the flexor tendons of the hand and is considered a medico-surgical emergency.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Infectious tenosynovitis is mostly caused by <i>Staphylococci</i>, <i>Streptococci</i>, Gram negatives, and following bite injury, <i>Eikenella</i> and <i>Pasteurella</i> species. Atypical organisms especially in immunocompromised patients are increasingly being reported like fungi and slowly or rapidly growing mycobacteria. Management can be conservative with intravenous antibiotics and close monitoring especially in mild cases. Minimally invasive catheter irrigation of the tendon sheath can be used with improved functional outcomes.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Suppurative tenosynovitis is an infection of the tendon sheath. Inoculation usually occurs following injury, puncture wounds, bites, recent surgery, or via hematogenous or contiguous spread of infection. Kanavel signs are helpful when evaluating patients. Hand surgeons should be promptly consulted for decision about need for surgical exploration. Uncomplicated cases can be treated with 7 to 14 days of an oral antibiotic. Smoking, diabetes, vascular disease, and advanced Michon stage infection are associated with higher risk of amputation or decreased mobility. Infectious diseases specialists should be consulted in the management of atypical presentations like fungal and mycobacterial tenosynovitis.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139093109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs): a Systematic Review and Meta-Analysis 接受布鲁顿酪氨酸激酶抑制剂（BTKIs）治疗的患者中的 HBV 再激活：系统回顾和 Meta 分析

IF 3.1 4区医学

Current Infectious Disease Reports Pub Date : 2024-01-03 DOI: 10.1007/s11908-023-00827-3

Ahmed Azzam, Heba Khaled, Basem Osama Ashry, Sarah Mohamed Hussein, Manar Osama, Ameer Ahmed, Omar Yousef, Anees Hjazeen, Ahmed A. Allam, Gellan Alaa Mohamed Kamel

{"title":"HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs): a Systematic Review and Meta-Analysis","authors":"Ahmed Azzam, Heba Khaled, Basem Osama Ashry, Sarah Mohamed Hussein, Manar Osama, Ameer Ahmed, Omar Yousef, Anees Hjazeen, Ahmed A. Allam, Gellan Alaa Mohamed Kamel","doi":"10.1007/s11908-023-00827-3","DOIUrl":"https://doi.org/10.1007/s11908-023-00827-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Bruton tyrosine kinase inhibitors (BTKIs) are immunosuppressive cancer therapies approved for the treatment of various mature B-cell malignancies. Hepatitis B virus reactivation (HBVr) is a known complication in patients with chronic or past HBV infection undergoing immunosuppressive chemotherapy. The present work aims to establish the correlation between HBVr and patients receiving BTKIs.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>This review included 18 studies. The overall incidence of HBVr was found to be 6.6% in patients with past HBV infections who received ibrutinib. Fourteen cases of HBVr were associated with ibrutinib (two occult hepatitis B infections and twelve past HBV infections). One case of HBV past infection was associated with zanubrutinib, and three cases were recorded for acalabrutinib (one chronic HBV and two past HBV). Most incidents occurred in males older than 60 years within the first year after initiating BTKIs. Three reported cases documented HBVr after discontinuing ibrutinib and zanubrutinib. Two deaths caused by HBVr in patients with past HBV infections were recorded (one for each of acalabrutinib and ibrutinib). Remarkably, HBV antiviral treatment normalized liver functions and eliminated serum HBV in most cases. It was reported that false negativity of HBsAg following reactivation occurred in two cases: one case was attributed to HBsAg escape mutations, and the other to the hook effect.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Our findings show that HBVr risk is intermediate in patients with past HBV infections who receive ibrutinib. Universal anti-HBV prophylaxis before initiating ibrutinib may be an option.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139092870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining International Critical Care Pharmacist Contributions to Sepsis and Exploring Variability 定义国际重症监护药剂师对败血症的贡献并探索差异性

IF 3.1 4区医学

Current Infectious Disease Reports Pub Date : 2023-12-20 DOI: 10.1007/s11908-023-00825-5

{"title":"Defining International Critical Care Pharmacist Contributions to Sepsis and Exploring Variability","authors":"","doi":"10.1007/s11908-023-00825-5","DOIUrl":"https://doi.org/10.1007/s11908-023-00825-5","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose of Review</h3> <p>To define international clinical pharmacist contributions to managing sepsis in critically unwell patients and explore variation.</p> </span> <span> <h3>Recent Findings</h3> <p>Clinical pharmacists improve clinical outcomes and cost efficiencies. They provide pharmaceutical advice on selection, administration, plus monitoring of antimicrobials and supportive therapies. Logistical activities reduce drug administration times. Guideline production, patient/clinician education, prescribing error identification, plus therapeutic optimisation activities are also reported.</p> </span> <span> <h3>Summary</h3> <p>A survey incorporating semi-structured interviews identified further antimicrobial stewardship, prescribing and digital contributions to optimise sepsis management. However, disparities associated with multidisciplinary team integration and intensive care unit service provision were found. Variability was attributed to multifaceted physical, social, financial, training and education themes. Findings empower collaborations between pharmacists and stakeholders to identify and overcome contribution barriers. Strategies to mitigate barriers and enhance sepsis contributions were envisaged by reported aspirations. These emphasised the importance of professional advocacy, interprofessional education and impactful implementation research.</p> </span>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibiotic Use at Hospital Discharge and Outpatient Antimicrobial Stewardship 出院时抗生素使用和门诊抗菌药物管理

IF 3.1 4区医学

Current Infectious Disease Reports Pub Date : 2023-11-20 DOI: 10.1007/s11908-023-00824-6

Mandee Noval, Colleen Burgoyne, Jacinta Chin, Kathryn Dzintars, Aileen Jimenez, Angela Perhac, Jessa Brenon

{"title":"Antibiotic Use at Hospital Discharge and Outpatient Antimicrobial Stewardship","authors":"Mandee Noval, Colleen Burgoyne, Jacinta Chin, Kathryn Dzintars, Aileen Jimenez, Angela Perhac, Jessa Brenon","doi":"10.1007/s11908-023-00824-6","DOIUrl":"https://doi.org/10.1007/s11908-023-00824-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Inappropriate and unnecessary antibiotic prescriptions are common in the outpatient setting and as patients transition from inpatient to outpatient care. This review is designed to discuss effective strategies aimed to improve appropriate antibiotic use during transitions of care and in the outpatient setting for high-priority syndrome areas including acute respiratory infections (ARI), urinary tract infections (UTI), skin and soft tissue infections (SSTI), and bone and joint infections (BJI).</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Unlike inpatient stewardship programs, outpatient stewardship practices are currently not standardized across many healthcare systems. Since starting an outpatient ASP can be overwhelming, many programs opt to start by focusing on a smaller subset of high-priority locations or syndromes where antibiotics may be inappropriately prescribed. Numerous studies have identified effective antimicrobial stewardship strategies that can be incorporated on transitions of care and in the outpatient setting; however, a multimodal approach combining several stewardship strategies is often cited as the most effective approach. Available syndrome-specific interventions include opportunities at time of diagnosis, order entry, and post-prescription which may be tailored to meet individual program needs.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Outpatient ASP interventions targeted at diagnostic stewardship, adjustments to duration of therapy, optimization of agent selection, and avoidance of intravenous therapy remain high-priority target areas to prevent inappropriate antibiotic use.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138534643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complex Outpatient Antimicrobial Therapy: Alternative Management Strategies and Outcomes 复杂门诊抗菌治疗:替代管理策略和结果

4区医学

Current Infectious Disease Reports Pub Date : 2023-11-04 DOI: 10.1007/s11908-023-00820-w

Tucker John Guy Smith, Peter Daniels, Barry Rittmann

引用次数: 0

Rebuilding for Tomorrow’s Outbreak: The State of Special Pathogen Preparedness in the USA in the Wake of COVID-19 为明天的疫情重建:COVID-19后美国特殊病原体防范状况

4区医学

Current Infectious Disease Reports Pub Date : 2023-11-01 DOI: 10.1007/s11908-023-00821-9

Jade B. Flinn, Amy D. Britton, Jennifer Garland, Jennifer Cuzzolina, Paul D. Biddinger, Vikramjit Mukherjee, Jonathan D. Grein

引用次数: 0

One Small Step (Down) for Antibiotics, One Giant Leap for Outpatient Therapy: The Role of Oral Antibiotics in Serious Bacterial Infections 抗生素的一小步，门诊治疗的一大步:口服抗生素在严重细菌感染中的作用

4区医学

Current Infectious Disease Reports Pub Date : 2023-10-31 DOI: 10.1007/s11908-023-00823-7

Jessica K. Ortwine, Wenjing Wei, Norman S. Mang, Brenton C. Hall, Helen Ding

引用次数: 0

The Opportunities and Challenges for Artificial Intelligence to Improve Sepsis Outcomes in the Paediatric Intensive Care Unit 人工智能改善儿科重症监护病房脓毒症预后的机遇与挑战

4区医学

Current Infectious Disease Reports Pub Date : 2023-10-31 DOI: 10.1007/s11908-023-00818-4

Abdullah Tarik Aslan, Budi Permana, Patrick N. A. Harris, Kuban D. Naidoo, Michael A. Pienaar, Adam D. Irwin

{"title":"The Opportunities and Challenges for Artificial Intelligence to Improve Sepsis Outcomes in the Paediatric Intensive Care Unit","authors":"Abdullah Tarik Aslan, Budi Permana, Patrick N. A. Harris, Kuban D. Naidoo, Michael A. Pienaar, Adam D. Irwin","doi":"10.1007/s11908-023-00818-4","DOIUrl":"https://doi.org/10.1007/s11908-023-00818-4","url":null,"abstract":"Abstract Purpose of Review To describe existing applications of artificial intelligence (AI) in sepsis management and the opportunities and challenges associated with its implementation in the paediatric intensive care unit. Recent Findings Over the last decade, significant advances have occurred in the use of AI techniques, particularly in relation to medical image analysis. Increasingly, these techniques are being applied to a broad array of datasets. The availability of both structured and unstructured data from electronic health records, omics data and digital technologies (for example, portable sensors) is rapidly extending the range of applications for AI. These techniques offer the exciting potential to improve the recognition of sepsis and to help us understand the pathophysiological pathways and therapeutic targets of sepsis. Summary Although AI has great potential to improve sepsis management in children, significant challenges need to be overcome before it can be successfully implemented to change healthcare delivery.","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135871689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays 下一步:用新一代分子测定法研究糖尿病足感染

4区医学

Current Infectious Disease Reports Pub Date : 2023-10-27 DOI: 10.1007/s11908-023-00822-8

Caitlin Sande, Zoë J. Boston, Lindsay R. Kalan, Meghan B. Brennan

{"title":"Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays","authors":"Caitlin Sande, Zoë J. Boston, Lindsay R. Kalan, Meghan B. Brennan","doi":"10.1007/s11908-023-00822-8","DOIUrl":"https://doi.org/10.1007/s11908-023-00822-8","url":null,"abstract":"Abstract Purpose of Review In 2019, the International Working Group on the Diabetic Foot voiced six concerns regarding the use of molecular microbiology techniques for routine diagnosis of infection complicating diabetic foot ulcers. The purpose of this review is to evaluate contemporary evidence addressing each of these concerns and describe promising avenues for continued development of molecular microbiology assays. Recent Findings Since 2019, the feasibility of conducting metagenomic and metatranscriptomic studies on diabetic foot ulcer samples has been shown. However, these preliminary studies used small samples with concerns for selection bias. We await larger-scale, longitudinal studies, potentially using the recently formed Diabetic Foot Consortium, to identify microbiome profiles associated with infection and patient outcomes. How these results would translate into a clinical diagnostic requires further clarification. Summary High-throughput molecular microbiology techniques are not yet ready for clinical adoption as first-line diagnostics. However, moving from amplicon sequencing to metagenomic and metatranscriptomic studies has the potential to significantly accelerate development of assays that might meaningfully impact patient care.","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136235252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should We Tap That? Aspirates and Antibiotics: An Update on Septic Bursitis 我们应该利用它吗?吸入剂和抗生素:化脓性滑囊炎的最新进展

4区医学

Current Infectious Disease Reports Pub Date : 2023-10-27 DOI: 10.1007/s11908-023-00819-3

Rachel Weihe, Mitchell C. Birt, Wissam El Atrouni

引用次数: 0